Spectrum Pharmaceuticals has completed the transaction acquiring control of RIT Oncology, LLC, to commercialize Zevalin ([90Y]-ibritumomab tiuxetan) in the U.S. In connection with the closing, Spectrum will pay a total of $16.5 million (subject to adjustments based on outstanding liabilities and obligations). No further payments or milestones will be paid to RIT. Zevalin is currently approved for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin&...